Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

61. The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial Full Text available with Trip Pro

The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial To investigate the effectiveness of exercise as treatment for vasomotor menopausal symptoms.Three-group randomised controlled trial, two exercise interventions and a control group.Primary Care, West Midlands UK.Perimenopausal and postmenopausal women experiencing at least five hot flushes/night sweats per day and not taken MHT in previous 3 months were recruited from 23 general (...) practices.Participants in both exercise interventions groups were offered two face-to-face consultations with a physical activity facilitator to support engagement in regular exercise. In addition, one exercise group received a menopause-specific information DVD and written materials to encourage regular exercise and the other exercise group was offered the opportunity to attend exercise social support groups in their communities. Interventions lasted 6 months.The primary outcome was frequency of hot flushes/night

2015 EvidenceUpdates Controlled trial quality: uncertain

62. Menopause: diagnosis and management

Menopause: diagnosis and management Menopause: diagnosis and management Menopause: diagnosis and management NICE guideline Published: 12 November 2015 nice.org.uk/guidance/ng23 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Menopause: diagnosis and management (NG23) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 30Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Individualised care 5 1.2 Diagnosis

2015 National Institute for Health and Clinical Excellence - Clinical Guidelines

63. Treatment of Symptoms of the Menopause

Treatment of Symptoms of the Menopause '); '); Treatment of the Symptoms of Menopause Guideline Resources | Endocrine Society Hormone Science to Health / › › › Guidelines and Clinical Practice Section + Full Guideline: JCEM | November 2015 Cynthia A. Stuenkel (chair), Susan R. Davis, Anne Gompel, Mary Ann Lumsden, M. Hassan Murad, JoAnn V. Pinkerton, and Richard J. Santen The 2015 guideline addresses: General evaluation and health considerations for menopausal women Evaluating hormone (...) replacement options and associated risks Monitoring patients during hormone therapies Treating genitourinary syndrome Resources | ENDO 2015 | Guideline Central | Hormone Health Network | Endocrine Society Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline | ENDO 2015 Essential Points The Endocrine Society recommends that women with a uterus who decide to undergo menopausal hormone therapy with estrogen and progestogen be informed about risks and benefits, including

2015 The Endocrine Society

64. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society

Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society Copyright @ 2015 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. POSITION STATEMENT Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society Abstract Objective: To update and expand The North American Menopause Society’s evidence-based position (...) on nonhormonal management of menopause-associated vasomotor symptoms (VMS), previously a portion of the position statement on the management of VMS. Methods: NAMS enlisted clinical and research experts in the field and a reference librarian to identify and review available evidence. Five different electronic search engines were used to cull relevant literature. Using the literature, experts created a document for final approval by the NAMS Board of Trustees. Results: Nonhormonal management of VMS

2015 The North American Menopause Society

65. Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women ? first line in combination with letrozole

Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women ? first line in combination with letrozole Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole NIHR HSC Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Breast Neoplasms; Female; Humans Language Published English

2014 Health Technology Assessment (HTA) Database.

66. Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women

Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women Denosumab versus bifosfonatos para el tratamiento de la osteoporosis en mujeres post menopáusicas [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Denosumab versus bifosfonatos para el tratamiento de la osteoporosis en mujeres post menopáusicas [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Pichon Riviere (...) en mujeres post menopáusicas. [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N° 308. 2013 Authors' objectives To assess the available evidence on the efficacy, safety and coverage policy related aspect for denosumab versus bisphosphonates in decreasing the risk of fractures due to post-menopausal osteoporosis. Authors' conclusions

2014 Health Technology Assessment (HTA) Database.

67. Managing Menopause Chapter 1 Assessment and Risk Management of Menopausal Women Full Text available with Trip Pro

Managing Menopause Chapter 1 Assessment and Risk Management of Menopausal Women Managing Menopause Chapter 1 Assessment and Risk Management of Menopausal Women - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S6–S15 Managing Menopause Chapter 1 Assessment and Risk Management of Menopausal Women DOI: To view the full text, please login as a subscribed user or . Click to view the full (...) text on ScienceDirect. Figures Menopause is an important milestone and may be one of the first times a woman seeks medical advice around issues of long-term health promotion and disease prevention. Women typically begin to experience menopausal symptoms between 40 and 58 years of age, spending at least one third of their lives after menopause. 1 The 3 main causes of illness and disability in developed countries for postmenopausal women are CVD, cancer, and osteoporosis-associated fractures. 2

2014 Society of Obstetricians and Gynaecologists of Canada

68. Managing Menopause Abstract and Summary Statement Full Text available with Trip Pro

Managing Menopause Abstract and Summary Statement Managing Menopause Abstract and Summary Statement - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S1–S5 Managing Menopause Abstract and Summary Statement PRINCIPAL AUTHORS, x Robert Reid , MD Kingston ON x Beth L. Abramson , MD Toronto ON x Jennifer Blake , MD Toronto ON x Sophie Desindes , MD Sherbrooke QC x Sylvie Dodin , MD Quebec QC (...) x Shawna Johnston , MD Kingston ON x Timothy Rowe , MB BS Vancouver BC x Namrita Sodhi , MD Toronto ON x Penny Wilks , ND Dundas ON x Wendy Wolfman , MD Toronto ON x MENOPAUSE AND OSTEOPOROSIS WORKING GROUP x Michel Fortier , MD (Co-Chair) x Michel Fortier , x Robert Reid , MD (Co-Chair) x Robert Reid , x Beth L. Abramson , MD x Beth L. Abramson , x Jennifer Blake , MD x Jennifer Blake , x Sophie Desindes , MD x Sophie Desindes , x Sylvie Dodin , MD x Sylvie Dodin , x Lisa Graves , MD x Lisa

2014 Society of Obstetricians and Gynaecologists of Canada

69. Managing Menopause Chapter 2 Cardiovascular Disease

Managing Menopause Chapter 2 Cardiovascular Disease Managing Menopause Chapter 2 Cardiovascular Disease - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S16–S22 Managing Menopause Chapter 2 Cardiovascular Disease DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Consensus is emerging from the controversy and confusion (...) that has occupied the past decade regarding the effects of postmenopausal HT on CVD. Since the publication of the SOGC’s Canadian Consensus Conference on Menopause in 2006, 1 several publications have shed additional light on this subject. To access this article, please choose from the options below Log In Register Purchase access to this article Claim Access If you are a current subscriber with Society Membership or an Account Number, . Subscribe to this title to gain access to this and all other

2014 Society of Obstetricians and Gynaecologists of Canada

70. Managing Menopause Chapter 3 Menopausal Hormone Therapy and Breast Cancer Full Text available with Trip Pro

Managing Menopause Chapter 3 Menopausal Hormone Therapy and Breast Cancer Managing Menopause Chapter 3 Menopausal Hormone Therapy and Breast Cancer - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S23–S30 Managing Menopause Chapter 3 Menopausal Hormone Therapy and Breast Cancer DOI: To view the full text, please login as a subscribed user or . Click to view the full text (...) on ScienceDirect. Breast cancer accounts for almost 25% of all cancers diagnosed in women (1.4 million cases worldwide survival differences can be attributed in part to early-detection programs and access to treatment, other factors in 2008), and it is clearly the greatest concern for women considering menopausal HT to ease their transition into menopause. The cumulative incidence of breast cancer among women in Europe and North America is about 2.7% by age 55, about 5.0% by age 65, and about 7.7% by age 75. 1

2014 Society of Obstetricians and Gynaecologists of Canada

71. Managing Menopause Chapter 4 Vasomotor Symptoms

Managing Menopause Chapter 4 Vasomotor Symptoms Managing Menopause Chapter 4 Vasomotor Symptoms - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S31–S34 Managing Menopause Chapter 4 Vasomotor Symptoms DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. VMS affect 60% to 80% of women entering menopause. 1 Hot flashes are common (...) in the perimenopausal transition, when ovarian activity may be intermittent, and they have also been documented during the luteal and menstrual phases of the cycle in women with premenstrual dysphoric disorder. 2 After menopause, it is important to be alert to atypical features or to a lack of response to effective therapy, which might indicate an alternative cause of the symptoms. The differential diagnosis includes hyperthyroidism, anxiety, panic attack, hypertension, emotional flushing, neurologic flushing

2014 Society of Obstetricians and Gynaecologists of Canada

72. Managing Menopause Chapter 5 Urogenital Health

Managing Menopause Chapter 5 Urogenital Health Managing Menopause Chapter 5 Urogenital Health - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S35–S41 Managing Menopause Chapter 5 Urogenital Health DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. The vagina, lower urinary tract, and pelvic floor have the same embryologic (...) origin, and therefore all contain estrogen receptors and undergo atrophy in the estrogen-deficient state of menopause. The concept of urogenital aging encompasses the altered structure and function of the urogenital tissues under the combined influence of estrogen loss from menopause and tissue aging. Although tissue aging is both insidious and inevitable, the effect of estrogen loss on the urogenital tissues is relatively rapid and, at least to some extent, reversible with ET. To access this article

2014 Society of Obstetricians and Gynaecologists of Canada

73. Managing Menopause Chapter 6 Prescription Therapeutic Agents Full Text available with Trip Pro

Managing Menopause Chapter 6 Prescription Therapeutic Agents Managing Menopause Chapter 6 Prescription Therapeutic Agents - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S42–S50 Managing Menopause Chapter 6 Prescription Therapeutic Agents DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. In November 1929, clinicians

2014 Society of Obstetricians and Gynaecologists of Canada

74. Managing Menopause Chapter 7 Ongoing Management of Menopausal Women and Those With Special Considerations

Managing Menopause Chapter 7 Ongoing Management of Menopausal Women and Those With Special Considerations Managing Menopause Chapter 7 Ongoing Management of Menopausal Women and Those With Special Considerations - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S51–S58 Managing Menopause Chapter 7 Ongoing Management of Menopausal Women and Those With Special Considerations DOI: To view (...) the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Figures Figure 7.1 The Stages of Reproductive Aging Workshop + 10 staging system for reproductive aging in women The goal of this chapter is to give practical tips to health care providers for the management of symptomatic women during and after the menopausal transition, concerning mostly the initiation and follow-up of HT. The reader may refer to previous chapters for more extensive literature review

2014 Society of Obstetricians and Gynaecologists of Canada

75. Managing Menopause Chapter 8 Sexuality and Menopause

Managing Menopause Chapter 8 Sexuality and Menopause Managing Menopause Chapter 8 Sexuality and Menopause - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S59–S73 Managing Menopause Chapter 8 Sexuality and Menopause DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Figures Figure 8.1 Sexual problems and personal distress (...) by age In gynaecologic practice many peri- and postmenopausal women present to the physician with new complaints of changes in sexual desire or pain with intercourse that affects their relationships and quality of life. 1,2 Postmenopausal women are interested in sex for physical pleasure, intimacy, and expression of love, as well as to please their partner. 3 Maintenance of sexuality is important for the well-being of women as they navigate the emotional and physical challenges of menopause. 2,4

2014 Society of Obstetricians and Gynaecologists of Canada

76. Managing Menopause Chapter 9 Complementary and Alternative Medicine (CAM)

Managing Menopause Chapter 9 Complementary and Alternative Medicine (CAM) Managing Menopause Chapter 9 Complementary and Alternative Medicine (CAM) - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S74–S80 Managing Menopause Chapter 9 Complementary and Alternative Medicine (CAM) DOI: To view the full text, please login as a subscribed user or . Click to view the full text

2014 Society of Obstetricians and Gynaecologists of Canada

77. Osteoporosis in Menopause

Osteoporosis in Menopause Osteoporosis in Menopause - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Pages 839–840 Osteoporosis in Menopause PRINCIPAL AUTHORS, x Aliya Khan , MD Hamilton ON x Michel Fortier , MD Quebec QC x MENOPAUSE AND OSTEOPOROSIS WORKING GROUP x Michel Fortier , MD (Co-Chair) x Michel Fortier , x Robert Reid , MD (Co-Chair) x Robert Reid , x Beth L. Abramson , MD x Beth L. Abramson , x (...) osteoporosis. Evidence Published literature was retrieved through searches of PubMed and The Cochrane Library on August 30 and September 18, 2012, respectively. The strategy included the use of appropriate controlled vocabulary (e.g., oteoporosis, bone density, menopause) and key words (e.g., bone health, bone loss, BMD). Results were restricted to systematic reviews, practice guidelines, randomized and controlled clinical trials, and observational studies published in English or French. The search

2014 Society of Obstetricians and Gynaecologists of Canada

78. Quantitative study?other: In menopausal women physical activity and taking dietary supplements may protect against coronary artery disease

Quantitative study?other: In menopausal women physical activity and taking dietary supplements may protect against coronary artery disease In menopausal women physical activity and taking dietary supplements may protect against coronary artery disease | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In menopausal women physical activity and taking dietary supplements may protect against coronary artery disease Article Text Nursing issues

2014 Evidence-Based Nursing

79. Systematic review and meta-analysis: Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms

Systematic review and meta-analysis: Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms Article Text Therapeutics Systematic review and meta-analysis Isoflavones hold limited promise

2014 Evidence-Based Medicine

80. Menopause Chapter 8: Prescription Therapies

Menopause Chapter 8: Prescription Therapies Chapter 8: Prescription Therapies | | | | Chapter 8: Prescription Therapies > > > CONTRACEPTIVES Key Points Despite a decline in fertility, women of older reproductive age who do not wish to conceive should use effective contraception until 1 year after the final menstrual period. Long-acting reversible contraceptive methods, which include the copper intrauterine device (IUD), the two levonorgestrel intrauterine systems, and the etonogestrel subdermal (...) with a uterus. Systemic HT and low-dose vaginal ET are very effective treatments for moderate to severe symptoms of vulvar and vaginal atrophy (vaginal dryness, dyspareunia, and atrophic vaginitis). The estrogen agonist/antagonist ospemifene is a new oral agent approved for this indication. Recommendations for Clinical Care The lowest dose of HT should be used for the shortest duration needed to manage menopausal symptoms. Individualization is important in the decision to use HT and should incorporate

2014 The North American Menopause Society